Amgen Inc. $AMGN Shares Sold by Strs Ohio

Key Points

• Strs Ohio cut its Amgen stake by 8.5%76.50% of AMGN is owned by institutional investors and hedge funds.
• Amgen reported a Q1 beat with $5.15 EPS (vs. ~$4.77 consensus) and $8.62B revenue, set FY‑2026 EPS guidance of $21.70–$23.10, and the stock traded down about 4.7% following the update.
• Goldman Sachs lifted its price target to $425 and maintained a Buy, but the aggregate analyst view is a "Hold" with an average PT of $357.54, while regulatory risk rose after the FDA proposed withdrawing Tavneos approval.

Strs Ohio reduced its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,887 shares of the medical research company's stock after selling 12,909 shares during the period. Strs Ohio's holdings in Amgen were worth $45,459,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMGN. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the fourth quarter worth $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter worth $33,000. Cloud Capital Management LLC acquired a new position in shares of Amgen during the third quarter worth $34,000. Ares Financial Consulting LLC acquired a new position in shares of Amgen during the fourth quarter worth $34,000. Finally, Saranac Partners Ltd acquired a new position in shares of Amgen during the third quarter worth $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AMGN. The Goldman Sachs Group upped their price target on shares of Amgen from $415.00 to $425.00 and gave the company a "buy" rating in a report on Friday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a report on Thursday, February 5th. Mizuho upped their price target on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. Sanford C. Bernstein cut shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. Finally, Guggenheim upped their price target on shares of Amgen from $347.00 to $351.00 and gave the company a "neutral" rating in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $357.54.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Trading Down 4.7%

AMGN opened at $329.82 on Friday. The stock has a market capitalization of $178.00 billion, a PE ratio of 23.18, a P/E/G ratio of 3.42 and a beta of 0.47. The firm's fifty day moving average price is $358.07 and its 200 day moving average price is $340.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.16 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.